212 results on '"Mitsuhiro Abe"'
Search Results
2. Radiation-induced organizing pneumonia caused by carbon-ion radiotherapy for lung cancer
- Author
-
Yu Shionoya, Megumi Katsumata, Hajime Kasai, Kohei Shikano, Aoi Hino, Masaki Suzuki, Mitsuhiro Abe, and Takuji Suzuki
- Subjects
Lung cancer ,Radiation-induced organizing pneumonia ,Carbon-ion radiotherapy ,Corticosteroids ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Radiation-induced organizing pneumonia is a rare complication of radiation therapy for thoracic cancer. Carbon-ion radiotherapy, an emerging treatment modality for early-stage lung cancer treatment, can also cause lung injuries. However, as cases of radiation-induced organizing pneumonia caused by carbon-ion radiotherapy for lung cancer have not been reported, its clinical features remain unclear. A 69-year-old woman was referred to our hospital 11 months after being diagnosed with early lung cancer due to refractory pneumonitis induced by carbon-ion radiotherapy. She had developed fever and dyspnea 4 months after undergoing carbon-ion radiotherapy and was subsequently diagnosed with radiation pneumonitis. The administration of oral prednisolone resulted in improvement. However, she relapsed each time the dose of prednisolone was tapered. She was diagnosed with radiation-induced organizing pneumonia caused by carbon-ion radiotherapy for lung cancer based on the clinical course and the results of the examination performed at our hospital. An improvement was observed after administering methylprednisolone (1000 mg/d) for 3 days. The dose of oral prednisolone was slowly tapered over a period of ≥6 months with no relapse. Organizing pneumonia caused by carbon-ion radiotherapy for lung cancer is treatable with corticosteroids; however, tapering the dose of corticosteroids may lead to relapse.
- Published
- 2024
- Full Text
- View/download PDF
3. Identification of kynurenine and quinolinic acid as promising serum biomarkers for drug-induced interstitial lung diseases
- Author
-
Yuchen Sun, Kosuke Saito, Atsuhito Ushiki, Mitsuhiro Abe, Yoshinobu Saito, Takeru Kashiwada, Yasushi Horimasu, Akihiko Gemma, Koichiro Tatsumi, Noboru Hattori, Kenji Tsushima, Kazuhisa Takemoto, Rika Ishikawa, Toshiko Momiyama, Shin-ichiro Matsuyama, Noriaki Arakawa, Hirotoshi Akane, Takeshi Toyoda, Kumiko Ogawa, Motonobu Sato, Kazuhiko Takamatsu, Kazuhiko Mori, Takayoshi Nishiya, Takashi Izumi, Yasuo Ohno, Yoshiro Saito, and Masayuki Hanaoka
- Subjects
Kynurenine ,Quinolinic acid ,Kynurenine/tryptophan ratio ,Drug-induced interstitial lung diseases ,Biomarker ,Metabolomics ,Diseases of the respiratory system ,RC705-779 - Abstract
Abstract Background Drug-induced interstitial lung disease (DILD) is a lung injury caused by various types of drugs and is a serious problem in both clinical practice and drug development. Clinical management of the condition would be improved if there were DILD-specific biomarkers available; this study aimed to meet that need. Methods Biomarker candidates were identified by non-targeted metabolomics focusing on hydrophilic molecules, and further validated by targeted approaches using the serum of acute DILD patients, DILD recovery patients, DILD-tolerant patients, patients with other related lung diseases, and healthy controls. Results Serum levels of kynurenine and quinolinic acid (and kynurenine/tryptophan ratio) were elevated significantly and specifically in acute DILD patients. The diagnostic potentials of these biomarkers were superior to those of conventional lung injury biomarkers, Krebs von den Lungen-6 and surfactant protein-D, in discriminating between acute DILD patients and patients with other lung diseases, including idiopathic interstitial pneumonia and lung diseases associated with connective tissue diseases. In addition to identifying and evaluating the biomarkers, our data showed that kynurenine/tryptophan ratios (an indicator of kynurenine pathway activation) were positively correlated with serum C-reactive protein concentrations in patients with DILD, suggesting the potential association between the generation of these biomarkers and inflammation. Our in vitro experiments demonstrated that macrophage differentiation and inflammatory stimulations typified by interferon gamma could activate the kynurenine pathway, resulting in enhanced kynurenine levels in the extracellular space in macrophage-like cell lines or lung endothelial cells. Extracellular quinolinic acid levels were elevated only in macrophage-like cells but not endothelial cells owing to the lower expression levels of metabolic enzymes converting kynurenine to quinolinic acid. These findings provide clues about the molecular mechanisms behind their specific elevation in the serum of acute DILD patients. Conclusions The serum concentrations of kynurenine and quinolinic acid as well as kynurenine/tryptophan ratios are promising and specific biomarkers for detecting and monitoring DILD and its recovery, which could facilitate accurate decisions for appropriate clinical management of patients with DILD.
- Published
- 2024
- Full Text
- View/download PDF
4. Prognostic impact of the cross-sectional area of the erector spinae muscle in patients with pleuroparenchymal fibroelastosis
- Author
-
Shinsuke Kitahara, Mitsuhiro Abe, Chiyoko Kono, Noriko Sakuma, Daisuke Ishii, Takeshi Kawasaki, Jun Ikari, and Takuji Suzuki
- Subjects
Medicine ,Science - Abstract
Abstract Pleuroparenchymal fibroelastosis (PPFE) progresses slowly but sometimes relatively quickly, leading to decreased activities of daily living (ADL) and muscle weakness. Skeletal muscle atrophy and muscle weakness in chronic obstructive pulmonary disease (COPD) patients may be caused by cachexia and are associated with reduced ADLs and increased risk of death. However, the association between skeletal muscle mass and the prognosis of PPFE patients remains unknown. We retrospectively analysed the clinical significance of the cross-sectional area of the erector spinae muscle (ESMCSA), a skeletal muscle index, and predictors of mortality within 3 years in PPFE 51 patients, idiopathic pulmonary fibrosis (IPF) 52 patients and COPD 62 patients. PPFE patients had significantly lower ESMCSA than IPF or COPD patients, and lower ESMCSA (
- Published
- 2023
- Full Text
- View/download PDF
5. A retrospective comparison between digital to conventional drainage systems for secondary spontaneous pneumothorax related to diffuse interstitial lung disease
- Author
-
Kohei Shikano, Mitsuhiro Abe, Ryutaro Hirama, Shinsuke Kitahara, Kanae Maruyama, Dai Horiuchi, Noriko Sakuma, Daisuke Ishii, Takeshi Kawasaki, Hidenori Nakamura, and Takuji Suzuki
- Subjects
chest tubes ,drainage ,interstitial lung disease ,interstitial pneumonia ,pneumothorax ,Diseases of the respiratory system ,RC705-779 - Abstract
Abstract Introduction Secondary spontaneous pneumothorax (SSP) occurs as one of the complications associated with interstitial pneumonia (IP). Chest drainage is performed when there is a large volume of air in the pleural space. Notably, SSP with IP (SSP‐IP) is frequently not curable by chest drainage only. A digital drainage system (DDS) provides an objective evaluation of air leakage and maintains a pre‐determined negative pressure, compared to an analog drainage system (ADS). Few studies have reported the effectiveness of DDS in the treatment of SSP‐IP. This study aimed to assess the usefulness of DDS for SSP‐IP. Methods This retrospective study included patients with SSP‐IP who had undergone chest drainage. We reviewed the included patients' medical records, laboratory data, computed tomography findings, and pulmonary function data. Results DDS was used in 24 patients and ADS in 49 patients. The mean duration of chest drainage was 11.4 ± 1.9 days in the DDS group and 14.2 ± 1.3 days in the ADS group, which was not significantly different (p = 0.218). Surgery, pleurodesis, and/or factor XIII administration were performed in 40 patients. Additionally, five (20.8%) patients in the DDS group and nine (18.4%) in the ADS group had a recurrence of pneumothorax within 4 weeks (p = 1.000). One patient (14%) in the DDS group and six (12.2%) in the ADS group (p = 0.414) were cured of pneumothorax but later died. Conclusion DDS did not demonstrate a significant difference in the shortening of chest drainage duration. Further study is needed to validate the results of this study.
- Published
- 2023
- Full Text
- View/download PDF
6. Effects of Anti-Fibrotic Drugs on Transcriptome of Peripheral Blood Mononuclear Cells in Idiopathic Pulmonary Fibrosis
- Author
-
Daisuke Ishii, Takeshi Kawasaki, Hironori Sato, Koichiro Tatsumi, Takuro Imamoto, Keiichiro Yoshioka, Mitsuhiro Abe, Yoshinori Hasegawa, Osamu Ohara, and Takuji Suzuki
- Subjects
idiopathic pulmonary fibrosis ,peripheral blood mononuclear cells (PBMCs) ,RNA sequencing ,transcriptome ,pirfenidone ,nintedanib ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Two anti-fibrotic drugs, pirfenidone (PFD) and nintedanib (NTD), are currently used to treat idiopathic pulmonary fibrosis (IPF). Peripheral blood mononuclear cells (PBMCs) are immunocompetent cells that could orchestrate cell–cell interactions associated with IPF pathogenesis. We employed RNA sequencing to examine the transcriptome signature in the bulk PBMCs of patients with IPF and the effects of anti-fibrotic drugs on these signatures. Differentially expressed genes (DEGs) between “patients with IPF and healthy controls” and “before and after anti-fibrotic treatment” were analyzed. Enrichment analysis suggested that fatty acid elongation interferes with TGF-β/Smad signaling and the production of oxidative stress since treatment with NTD upregulates the fatty acid elongation enzymes ELOVL6. Treatment with PFD downregulates COL1A1, which produces wound-healing collagens because activated monocyte-derived macrophages participate in the production of collagen, type I, and alpha 1 during tissue damage. Plasminogen activator inhibitor-1 (PAI-1) regulates wound healing by inhibiting plasmin-mediated matrix metalloproteinase activation, and the inhibition of PAI-1 activity attenuates lung fibrosis. DEG analysis suggested that both the PFD and NTD upregulate SERPINE1, which regulates PAI-1 activity. This study embraces a novel approach by using RNA sequencing to examine PBMCs in IPF, potentially revealing systemic biomarkers or pathways that could be targeted for therapy.
- Published
- 2024
- Full Text
- View/download PDF
7. Identification and characterization of lysophosphatidylcholine 14:0 as a biomarker for drug-induced lung disease
- Author
-
Kosuke Saito, Akihiko Gemma, Koichiro Tatsumi, Noboru Hattori, Atsuhito Ushiki, Kenji Tsushima, Yoshinobu Saito, Mitsuhiro Abe, Yasushi Horimasu, Takeru Kashiwada, Kazuhiko Mori, Motonobu Sato, Takayoshi Nishiya, Kazuhiko Takamatsu, Yuchen Sun, Noriaki Arakawa, Takashi Izumi, Yasuo Ohno, Yoshiro Saito, and Masayuki Hanaoka
- Subjects
Medicine ,Science - Abstract
Abstract Drug-induced interstitial lung disease (DILD) occurs when drug exposure causes inflammation of the lung interstitium. DILD can be caused by different types of drugs, and some DILD patterns results in a high mortality rate; hence, DILD poses a serious problem in clinical practice as well as drug development, and strategies to diagnose and distinguish DILD from other lung diseases are necessary. We aimed to identify novel biomarkers for DILD by performing lipidomics analysis on plasma samples from patients with acute and recovery phase DILD. Having identified lysophosphatidylcholines (LPCs) as candidate biomarkers for DILD, we determined their concentrations using validated liquid chromatography/mass spectrometry biomarker assays. In addition, we evaluated the ability of LPCs to discriminate patients with acute phase DILD from those with recovery phase DILD, DILD-tolerant, or other lung diseases, and characterized their association with clinical characteristics. Lipidomics analysis revealed a clear decrease in LPC concentrations in the plasma of patients with acute phase DILD. In particular, LPC(14:0) had the highest discriminative index against recovery phase and DILD-tolerant patients. LPC(14:0) displayed no clear association with causal drugs, or subjects’ backgrounds, but was associated with disease severity. Furthermore, LPC(14:0) was able to discriminate between patients with DILD and other lung diseases, including idiopathic interstitial pneumonia and lung disease associated with connective tissue disease. LPC(14:0) is a promising biomarker for DILD that could improve the diagnosis of DILD and help to differentiate DILD from other lung diseases, such as idiopathic interstitial pneumonia and connective tissue disease.
- Published
- 2022
- Full Text
- View/download PDF
8. Stratifin as a novel diagnostic biomarker in serum for diffuse alveolar damage
- Author
-
Noriaki Arakawa, Atsuhito Ushiki, Mitsuhiro Abe, Shinichiro Matsuyama, Yoshinobu Saito, Takeru Kashiwada, Yasushi Horimasu, Akihiko Gemma, Koichiro Tatsumi, Noboru Hattori, Kenji Tsushima, Keiko Miyashita, Kosuke Saito, Ryosuke Nakamura, Takeshi Toyoda, Kumiko Ogawa, Motonobu Sato, Kazuhiko Takamatsu, Kazuhiko Mori, Takayoshi Nishiya, Takashi Izumi, Yasuo Ohno, Yoshiro Saito, and Masayuki Hanaoka
- Subjects
Science - Abstract
No reliable serum biomarker for diffuse alveolar damage, a poor prognosis subtype of drug-induced interstitial lung disease, is currently available. Here, the authors show stratifin/14-3-3σ in serum is a promising biomarker for diagnosis of this type of disease.
- Published
- 2022
- Full Text
- View/download PDF
9. Prognostic value of lymphocyte counts in bronchoalveolar lavage fluid in patients with acute respiratory failure: a retrospective cohort study
- Author
-
Yasutaka Hirasawa, Taka-aki Nakada, Takashi Shimazui, Mitsuhiro Abe, Yuri Isaka, Masashi Sakayori, Kenichi Suzuki, Keiichiro Yoshioka, Takeshi Kawasaki, Jiro Terada, Kenji Tsushima, and Koichiro Tatsumi
- Subjects
Bronchoalveolar lavage fluid ,Acute respiratory failure ,Mortality ,Lymphocytes ,Medical emergencies. Critical care. Intensive care. First aid ,RC86-88.9 - Abstract
Abstract Background Cellular patterns in bronchoalveolar lavage fluid (BALF) are used to distinguish or rule out particular diseases in patients with acute respiratory failure (ARF). However, whether BALF cellular patterns can predict mortality or not is unknown. We test the hypothesis that BALF cellular patterns have predictive value for mortality in patients with ARF. Methods This was a retrospective single-center observational study conducted in a Japanese University Hospital. Consecutive patients (n = 78) with both pulmonary infiltrates and ARF who were examined by bronchoalveolar lavage (BAL) between April 2015 and May 2018 with at least 1 year of follow-up were analyzed. Primary analysis was receiver operating characteristic curve—area under the curve (ROC-AUC) analysis for 1-year mortality. Results Among the final sample size of 78 patients, survivors (n = 56) had significantly increased lymphocyte and eosinophil counts and decreased neutrophil counts in BALF compared with non-survivors (n = 22). Among the fractions, lymphocyte count was the most significantly different (30 [12-50] vs. 7.0 [2.9-13]%, P
- Published
- 2021
- Full Text
- View/download PDF
10. Clinical characteristics and risk factors of drug‐induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis
- Author
-
Ken Koshikawa, Jiro Terada, Mitsuhiro Abe, Shunichiro Iwasawa, Masashi Sakayori, Keiichiro Yoshioka, Yasutaka Hirasawa, Hajime Kasai, Yohei Kawasaki, Kenji Tsushima, and Koichiro Tatsumi
- Subjects
Alectinib ,anaplastic lymphoma kinase ,ceritinib ,crizotinib ,drug‐related side effects and adverse reactions ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background If anaplastic lymphoma kinase (ALK) gene rearrangement in lung cancer is identified, ALK‐tyrosine kinase inhibitors (ALK‐TKIs) can be an effective treatment. However, the details of drug‐induced lung injury (DILI) caused by ALK‐TKI, which can be a serious side effect of ALK‐TKIs, remains unclear. This study aimed to investigate the clinical features and the onset risk factors of DILI by ALK‐TKIs in clinical practice. Methods The clinical features of 56 consecutive patients who received crizotinib, alectinib, and/or ceritinib at our hospital from 2012 to 2018 were retrospectively examined. Among these, patients diagnosed with DILI due to ALK‐TKIs were evaluated in terms of clinical features and parameters. Each clinical parameter before the administration of ALK‐TKIs was compared between the DILI onset group and the non‐onset group. Results A total of seven cases were diagnosed with DILI due to ALK‐TKIs; no DILI‐related deaths were observed. Chest computed tomography (CT) scan findings identified six patients with the organizing pneumonia (OP) pattern and one with the hypersensitivity pneumonia pattern. The onset of DILI was significantly different in patients age ≥ 64 years and with a creatinine clearance
- Published
- 2020
- Full Text
- View/download PDF
11. Transcriptome Analysis of Peripheral Blood Mononuclear Cells in Pulmonary Sarcoidosis
- Author
-
Keiichiro Yoshioka, Hironori Sato, Takeshi Kawasaki, Daisuke Ishii, Takuro Imamoto, Mitsuhiro Abe, Yoshinori Hasegawa, Osamu Ohara, Koichiro Tatsumi, and Takuji Suzuki
- Subjects
RNA sequencing ,transcriptome analysis ,pulmonary sarcoidosis ,peripheral blood mononuclear cell ,granuloma formation ,Medicine (General) ,R5-920 - Abstract
BackgroundSarcoidosis is a granulomatous systemic disease of unknown etiology. Mononuclear cells such as macrophages or lymphocytes in lung tissue and hilar or mediastinal lymph nodes have been recognized to play an essential role in granuloma formation in pulmonary sarcoidosis. Peripheral blood mononuclear cells (PBMCs) consist of several immunocompetent cells and have been shown to play a mechanistic role in the pathogenesis of sarcoidosis. However, the genetic modifications that occur in bulk PBMCs of sarcoidosis remain to be elucidated.PurposeThis study aimed to explore the pathobiological markers of sarcoidosis in PBMCs by comparing the transcriptional signature of PBMCs from patients with pulmonary sarcoidosis with those of healthy controls by RNA sequencing.MethodsPBMC samples were collected from subjects with pulmonary sarcoidosis with no steroid/immunosuppressant drugs (n = 8) and healthy controls (n = 11) from August 2020 to April 2021, and RNA sequencing was performed with the PBMC samples.ResultsPrincipal component analysis using RNA sequencing datasets comparing pulmonary sarcoidosis with healthy controls revealed that the two groups appeared to be differentiated, in which 270 differentially expressed genes were found in PBMCs between sarcoidosis and healthy controls. Enrichment analysis for gene ontology suggested that some biological processes related to the pathobiology of sarcoidosis, such as cellular response to interleukin (IL)-1 and IFN-γ, regulation of IL-6 production, IL-8 secretion, regulation of mononuclear cell migration, and response to lipopolysaccharide, were involved. Enrichment analysis of the KEGG pathway indicated the involvement of tumor necrosis factor (TNF), toll-like receptor signaling, IL-17 signaling pathways, phagosomes, and ribosomes. Most of the genes involved in TNF and IL-17 signaling pathways and phagosomes were upregulated, while most of the ribosome-related genes were downregulated.ConclusionThe present study demonstrated that bulk gene expression patterns in PBMCs were different between patients with pulmonary sarcoidosis and healthy controls. The changes in the gene expression pattern of PBMCs could reflect the existence of sarcoidosis lesions and influence granuloma formation in sarcoidosis. These new findings are important to strengthen our understanding of the etiology and pathobiology of sarcoidosis and indicate a potential therapeutic target for sarcoidosis.
- Published
- 2022
- Full Text
- View/download PDF
12. A case of primary racemose hemangioma with endobronchial lesions demonstrating recurrent hemoptysis initially treated with bronchial arterial embolization
- Author
-
Shun Imai, Hajime Kasai, Toshihiko Sugiura, Jun Nagata, Takahide Toyoda, Shunya Shiohira, Kohei Shikano, Chiaki Kawame, Yusuke Kouchi, Masayuki Ota, Mitsuhiro Abe, Hidemi Suzuki, Jun-ichiro Ikeda, Ichiro Yoshino, and Takuji Suzuki
- Subjects
Primary racemose hemangioma ,Endobronchial lesion ,Bronchial arterial embolization (BAE) ,Recurrent hemoptysis ,Diseases of the respiratory system ,RC705-779 - Abstract
Primary racemose hemangioma of the bronchial artery (RHBA) is one of the causes of massive hemoptysis. A 72-year-old woman was admitted to our hospital with recurrent hemoptysis. Bronchoscopy showed an endobronchial lesion, and the angiography of the right bronchial arteries indicated RHBA. Bronchial arterial embolization (BAE) was performed to prevent hemoptysis. Although the endobronchial lesion shrank after the first BAE, the lesion re-increased and caused massive hemoptysis. A thoracoscopic right upper lobectomy was performed, and hemoptysis did not recur. Therefore, in cases of RHBA where there is recurrent hemoptysis and the endobronchial lesions that remain after BAE, additional treatments should be considered.
- Published
- 2022
- Full Text
- View/download PDF
13. Pneumocystis pneumonia in an immunocompetent patient developing a subacute disease course with central consolidation
- Author
-
Chiaki Kawame, Hidehiro Yokota, Kohei Shikano, Hajime Kasai, Masaki Suzuki, Mitsuhiro Abe, Takashi Kishimoto, Jun-ichiro Ikeda, Seiichiro Sakao, and Takuji Suzuki
- Subjects
Central consolidation ,Immunocompetent ,Pneumocystis jirovecii ,Pneumocystis pneumonia ,Diseases of the respiratory system ,RC705-779 - Abstract
Pneumocystis pneumonia (PCP) typically occurs in immunocompromised individuals and rarely presents in immunocompetent individuals. A 55-year-old man was referred to our hospital with cough and anorexia that persisted for 2 months. Chest computed tomography revealed bilateral central consolidation. He was diagnosed with PCP via bronchoscopy. His symptoms and imaging findings improved with the administration of only trimethoprim and sulfamethoxazole. Although he had non-alcoholic fatty liver disease, there were no other complications that could potentially cause immunodeficiency. It should be noted that PCP in immunocompetent individuals can have a subacute disease course presenting with bilateral central consolidation.
- Published
- 2022
- Full Text
- View/download PDF
14. Exacerbation of autoimmune pulmonary alveolar proteinosis that improved with lone treatment of complicating nontuberculous mycobacterial infection: A case report
- Author
-
Shunya Shiohira, Masashi Sakayori, Keiichiro Yoshioka, Hajime Kasai, Ryutaro Hirama, Mitsuhiro Abe, Hiroki Nishimura, and Takuji Suzuki
- Subjects
Antibiotics ,Exacerbation ,Mycobacterium avium complex ,Pulmonary alveolar proteinosis ,Diseases of the respiratory system ,RC705-779 - Abstract
Herein, we present the case of a 63-year-old man with autoimmune pulmonary alveolar proteinosis (APAP) complicated by Mycobacterium avium complex (MAC) infection. APAP was diagnosed based on serum anti-granulocyte-macrophage colony-stimulating factor antibody, bronchoalveolar lavage fluid (BALF) findings, and transbronchial lung biopsy. Nodular shadows with cavities were visible on chest CT images, and Mycobacterium intracellulare was identified by BALF culture. Rifampicin, ethambutol, and clarithromycin were administered, and 4 months later, the nodular shadows of MAC had disappeared, and APAP was remarkably improved. Thus, in cases of APAP exacerbation complicated with infections, such as MAC, control of the infections may improve APAP.
- Published
- 2021
- Full Text
- View/download PDF
15. Imaging cholesterol depletion at the plasma membrane by methyl-β-cyclodextrin
- Author
-
Mitsuhiro Abe and Toshihide Kobayashi
- Subjects
Biochemistry ,QD415-436 - Published
- 2021
- Full Text
- View/download PDF
16. Objective quantitative multidetector computed tomography assessments in patients with combined pulmonary fibrosis with emphysema: Relationship with pulmonary function and clinical events.
- Author
-
Masaki Suzuki, Naoko Kawata, Mitsuhiro Abe, Hajime Yokota, Rie Anazawa, Yukiko Matsuura, Jun Ikari, Shin Matsuoka, Kenji Tsushima, and Koichiro Tatsumi
- Subjects
Medicine ,Science - Abstract
BackgroundCombined pulmonary fibrosis with emphysema (CPFE) is a clinically meaningful syndrome characterized by coexisting upper-lobe emphysema and lower-lobe interstitial fibrosis. However, ambiguous diagnostic criteria and, particularly, the absence of objective methods to quantify emphysematous/fibrotic lesions in patients with CPFE confound the interpretation of the pathophysiology of this syndrome. We analyzed the relationship between objectively quantified computed tomography (CT) measurements and the results of pulmonary function testing (PFT) and clinical events in CPFE patients.Materials and methodsWe enrolled 46 CPFE patients who underwent CT and PFT. The extent of emphysematous lesions was obtained by calculating the percent of low attenuation area (%LAA). The extent of fibrotic lesions was calculated as the percent of high attenuation area (%HAA). %LAA and %HAA values were combined to yield the percent of abnormal area (%AA). We assessed the relationships between CT parameters and other clinical indices, including PFT results. Multivariate analysis was performed to examine the association between the CT parameters and clinical events.ResultsA greater negative correlation with percent predicted diffusing capacity of the lung for carbon monoxide (DLCO %predicted) existed for %AA (r = -0.73, p < 0.001) than for %LAA or %HAA alone. The %HAA value was inversely correlated with percent predicted forced vital capacity (r = -0.48, p < 0.001), percent predicted total lung capacity (r = -0.48, p < 0.01), and DLCO %predicted (r = -0.47, p < 0.01). Multivariate logistic regression analysis found that %AA showed the strongest association with hospitalization events (odds ratio = 1.20, 95% confidence interval = 1.01-1.54, p = 0.029).ConclusionQuantitative CT measurements reflected deterioration in pulmonary function and were associated with hospitalization in patients with CPFE. This approach could serve as a useful method to determine the extent of lung morphology, pathophysiology, and the clinical course of patients with CPFE.
- Published
- 2020
- Full Text
- View/download PDF
17. Validation of a new serum granulocyte–macrophage colony-stimulating factor autoantibody testing kit
- Author
-
Koh Nakata, Tatsuki Sugi, Keiko Kuroda, Kazutaka Yoshizawa, Toshinori Takada, Ryushi Tazawa, Takahiro Ueda, Ami Aoki, Mitsuhiro Abe, Koichiro Tatsumi, Ryosuke Eda, Shotaro Kondoh, Konosuke Morimoto, Takeshi Tanaka, Etsuro Yamaguchi, Ayumu Takahashi, Miku Oda, Haruyuki Ishii, Shinyu Izumi, Haruhito Sugiyama, Atsushi Nakagawa, Keisuke Tomii, Masaru Suzuki, Satoshi Konno, Shinya Ohkouchi, Taizou Hirano, Tomohiro Handa, Toyohiro Hirai, Yoshikazu Inoue, Toru Arai, Katsuaki Asakawa, Takuro Sakagami, Takahiro Tanaka, Ayako Mikami, and Nobutaka Kitamura
- Subjects
Medicine - Abstract
Very recently, a modest but significant efficacy of granulocyte–macrophage colony-stimulating factor (GM-CSF) inhalation therapy for the treatment of mild to moderate autoimmune pulmonary alveolar proteinosis (aPAP) has been reported. As the ability to measure the level of GM-CSF autoantibody (GMAb) in the serum is required to decide the indication for this therapy, we developed a high-performance GMAb testing kit for clinical use. As the kit succeeded in reducing nonspecific IgG binding to the ELISA plate, the predictive performance shown in the training study to discriminate aPAP patients from healthy subjects was perfect, providing a cut-off value of 1.65 U·mL−1 in 78 patients with aPAP and 90 healthy subjects in an operator-blinded manner using logistic regression analysis. As in the validation study, serum samples from another 213 patients with aPAP were also blinded and evaluated in an operator-blinded manner against external 207 samples from patients with other types of PAP and patients exhibiting various ground-glass opacities on chest high-resolution computed tomography that require discrimination from PAP. The logistic regression analysis of these validation data sets revealed values of 97.6% and 100% for specificity and sensitivity, respectively. Thus, this new GMAb testing kit is reliable for the diagnosis of aPAP and differential diagnosis of other lung diseases.
- Published
- 2020
- Full Text
- View/download PDF
18. Tocilizumab-effective multicentric Castleman's disease with infiltration of eosinophil and IgG4-positive plasma cells: A case report
- Author
-
Yusuke Katsumata, MD, Jun Ikari, MD, Nozomi Tanaka, MD, Mitsuhiro Abe, MD, Kenji Tsushima, MD, Yoko Yonemori, MD, and Koichiro Tatsumi, MD
- Subjects
Diseases of the respiratory system ,RC705-779 - Abstract
A 67-year-old woman with fever and cough was diagnosed with eosinophilic pneumonia because of eosinophilia and increased eosinophil levels in the bronchoalveolar lavage fluid and transbronchial biopsy lung specimens. However, prednisolone therapy at a previous hospital was ineffective. Histological findings from thoracoscopic lung and lymph node biopsies were consistent with multicentric Castleman's disease (MCD). Since specimens also showed prominent eosinophil and IgG4-positive plasma cell infiltration, it was difficult to distinguish IgG4-related disease (IgG4-RD) from MCD. Administration of prednisolone plus tocilizumab improved the symptoms and lung lesions, and prednisolone administration was successfully reduced and then terminated. The present case highlights the difficulty in diagnosing MCD and IgG4-RD, and suggests that combined administration of tocilizumab and prednisolone might be effective in such a case.
- Published
- 2018
- Full Text
- View/download PDF
19. Comparative Analysis of Single-Molecule Dynamics of TRPV1 and TRPV4 Channels in Living Cells
- Author
-
Yutaro Kuwashima, Masataka Yanagawa, Mitsuhiro Abe, Michio Hiroshima, Masahiro Ueda, Makoto Arita, and Yasushi Sako
- Subjects
TRPV channel ,single-molecule imaging ,diffusion ,endocytosis ,receptor oligomerization ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
TRPV1 and TRPV4, members of the transient receptor potential vanilloid family, are multimodal ion channels activated by various stimuli, including temperature and chemicals. It has been demonstrated that TRPV channels function as tetramers; however, the dynamics of the diffusion, oligomerization, and endocytosis of these channels in living cells are unclear. Here we undertook single-molecule time-lapse imaging of TRPV1 and TRPV4 in HEK 293 cells. Differences were observed between TRPV1 and TRPV4 before and after agonist stimulation. In the resting state, TRPV4 was more likely to form higher-order oligomers within immobile membrane domains than TRPV1. TRPV1 became immobile after capsaicin stimulation, followed by its gradual endocytosis. In contrast, TRPV4 was rapidly internalized upon stimulation with GSK1016790A. The selective loss of immobile higher-order oligomers from the cell surface through endocytosis increased the proportion of the fast-diffusing state for both subtypes. With the increase in the fast state, the association rate constants of TRPV1 and TRPV4 increased, regenerating the higher-order oligomers. Our results provide a possible mechanism for the different rates of endocytosis of TRPV1 and TRPV4 based on the spatial organization of the higher-order structures of the two TRPV channels.
- Published
- 2021
- Full Text
- View/download PDF
20. Mutation-Specific Mechanisms of Hyperactivation of Noonan Syndrome SOS Molecules Detected with Single-molecule Imaging in Living Cells
- Author
-
Yuki Nakamura, Nobuhisa Umeki, Mitsuhiro Abe, and Yasushi Sako
- Subjects
Medicine ,Science - Abstract
Abstract Noonan syndrome (NS) is a congenital hereditary disorder associated with developmental and cardiac defects. Some patients with NS carry mutations in SOS, a guanine nucleotide exchange factor (GEF) for the small GTPase RAS. NS mutations have been identified not only in the GEF domain, but also in various domains of SOS, suggesting that multiple mechanisms disrupt SOS function. In this study, we examined three NS mutations in different domains of SOS to clarify the abnormality in its translocation to the plasma membrane, where SOS activates RAS. The association and dissociation kinetics between SOS tagged with a fluorescent protein and the living cell surface were observed in single molecules. All three mutants showed increased affinity for the plasma membrane, inducing excessive RAS signalling. However, the mechanisms by which their affinity was increased were specific to each mutant. Conformational disorder in the resting state, increased probability of a conformational change on the plasma membrane, and an increased association rate constant with the membrane receptor are the suggested mechanisms. These different properties cause the specific phenotypes of the mutants, which should be rescuable with different therapeutic strategies. Therefore, single-molecule kinetic analyses of living cells are useful for the pathological analysis of genetic diseases.
- Published
- 2017
- Full Text
- View/download PDF
21. Binding of a pleurotolysin ortholog from Pleurotus eryngii to sphingomyelin and cholesterol-rich membrane domains[S]
- Author
-
Hema Balakrishna Bhat, Takuma Kishimoto, Mitsuhiro Abe, Asami Makino, Takehiko Inaba, Motohide Murate, Naoshi Dohmae, Atsushi Kurahashi, Kozo Nishibori, Fumihiro Fujimori, Peter Greimel, Reiko Ishitsuka, and Toshihide Kobayashi
- Subjects
lipid binding protein ,lipid raft ,membrane lipids ,sphingolipid ,pore forming toxins ,Biochemistry ,QD415-436 - Abstract
A mixture of sphingomyelin (SM) and cholesterol (Chol) exhibits a characteristic lipid raft domain of the cell membranes that provides a platform to which various signal molecules as well as virus and bacterial proteins are recruited. Several proteins capable of specifically binding either SM or Chol have been reported. However, proteins that selectively bind to SM/Chol mixtures are less well characterized. In our screening for proteins specifically binding to SM/Chol liposomes, we identified a novel ortholog of Pleurotus ostreatus, pleurotolysin (Ply)A, from the extract of edible mushroom Pleurotus eryngii, named PlyA2. Enhanced green fluorescent protein (EGFP)-conjugated PlyA2 bound to SM/Chol but not to phosphatidylcholine/Chol liposomes. Cell surface labeling of PlyA2-EGFP was abolished after sphingomyelinase as well as methyl-β-cyclodextrin treatment, removing SM and Chol, respectively, indicating that PlyA2-EGFP specifically binds cell surface SM/Chol rafts. Tryptophan to alanine point mutation of PlyA2 revealed the importance of C-terminal tryptophan residues for SM/Chol binding. Our results indicate that PlyA2-EGFP is a novel protein probe to label SM/Chol lipid domains both in cell and model membranes.
- Published
- 2013
- Full Text
- View/download PDF
22. A 1-Tb 4-b/cell 4-Plane 162-Layer 3-D Flash Memory With 2.4-Gb/s IO Interface.
- Author
-
Jonghak Yuh, Yen-Lung Jason Li, Heguang Li, Yoshihiro Oyama, Cynthia Hsu, Pradeep Anantula, Gwang Yeong Stanley Jeong, Anirudh Amarnath, Siddhesh Darne, Sneha Bhatia, Tianyu Tang, Aditya Arya, Naman Rastogi, Naoki Ookuma, Hiroyuki Mizukoshi, Alex Yap, Demin Wang, Steve Kim, Yonggang Wu, Min Peng, Jason Lu, Tommy Ip, Seema Malhotra, Taekeun Han, Masatoshi Okumura, Jiwen Liu, Jeongduk John Sohn, Hardwell Chibvongodze, Muralikrishna Balaga, Akihiro Matsuda, Chen Chen 0099, Indra K. V, V. S. N. K. Chaitanya G., Venky Ramachandra, Yosuke Kato, Ravi Kumar 0010, Huijuan Wang, Farookh Moogat, In-Soo Yoon, Kazushige Kanda, Takahiro Shimizu, Noboru Shibata, Kosuke Yanagidaira, Takuyo Kodama, Ryo Fukuda, Yasuhiro Hirashima, and Mitsuhiro Abe
- Published
- 2023
- Full Text
- View/download PDF
23. A 1-Tb 4b/Cell 4-Plane 162-Layer 3D Flash Memory With a 2.4-Gb/s I/O Speed Interface.
- Author
-
Jong Yuh, Jason Li 0001, Heguang Li, Yoshihiro Oyama, Cynthia Hsu, Pradeep Anantula, Stanley Jeong, Anirudh Amarnath, Siddhesh Darne, Sneha Bhatia, Tianyu Tang, Aditya Arya, Naman Rastogi, Naoki Ookuma, Hiroyuki Mizukoshi, Alex Yap, Demin Wang, Steve Kim, Yonggang Wu, Min Peng, Jason Lu, Tommy Ip, Seema Malhotra, David Han, Masatoshi Okumura, Jiwen Liu, John Sohn, Hardwell Chibvongodze, Muralikrishna Balaga, Aki Matsuda, Chakshu Puri, Chen Chen 0099, Indra K. V, Chaitanya G, Venky Ramachandra, Yosuke Kato, Ravi Kumar 0010, Huijuan Wang, Farookh Moogat, In-Soo Yoon, Kazushige Kanda, Takahiro Shimizu, Noboru Shibata, Takashi Shigeoka, Kosuke Yanagidaira, Takuyo Kodama, Ryo Fukuda, Yasuhiro Hirashima, and Mitsuhiro Abe
- Published
- 2022
- Full Text
- View/download PDF
24. 30.4 A 1Tb 3b/Cell 3D-Flash Memory in a 170+ Word-Line-Layer Technology.
- Author
-
Tsutomu Higuchi, Takuyo Kodama, Koji Kato, Ryo Fukuda, Naoya Tokiwa, Mitsuhiro Abe, Teruo Takagiwa, Yuki Shimizu, Junji Musha, Katsuaki Sakurai, Jumpei Sato, Tetsuaki Utsumi, Kazuhide Yoneya, Yasuhiro Suematsu, Toshifumi Hashimoto, Takeshi Hioka, Kosuke Yanagidaira, Masatsugu Kojima, Junya Matsuno, Kei Shiraishi, Kensuke Yamamoto, Shintaro Hayashi, Tomoharu Hashiguchi, Kazuko Inuzuka, Akio Sugahara, Mitsuaki Honma, Keiji Tsunoda, Kazumasa Yamamoto, Takahiro Sugimoto, Tomofumi Fujimura, Mizuki Kaneko, Hiroki Date, Osamu Kobayashi, Takatoshi Minamoto, Ryoichi Tachibana, Itaru Yamaguchi, Juan Lee, Venky Ramachandra, Srinivas Rajendra, Tianyu Tang, Siddhesh Darne, Jiwang Lee, Jason Li 0001, Toru Miwa, Ryuji Yamashita, Hiroshi Sugawara, Naoki Ookuma, Masahiro Kano, Hiroyuki Mizukoshi, Yuki Kuniyoshi, Mitsuyuki Watanabe, Kei Akiyama, Hirotoshi Mori, Akira Arimizu, Yoshito Katano, Masakazu Ehama, Hiroshi Maejima, Koji Hosono, and Masahiro Yoshihara
- Published
- 2021
- Full Text
- View/download PDF
25. Severe Bacterial Pneumonia Due to Legionella longbeachae Transmitted from Potting Soil in Japan.
- Author
-
Hidemi Ogawa, Kenichiro Takeda, Ryotaro Yoneoka, Kohei Shikano, Mitsuhiro Abe, Hajime Kasai, and Takuji Suzuki
- Published
- 2024
- Full Text
- View/download PDF
26. A 65-Year-Old Man with Refractory Hemoptysis Associated with Chronic Progressive Pulmonary Aspergillosis Who Failed to Respond to Combined Endobronchial Occlusion and Bronchial Artery Embolization: A Case Report and Literature Review.
- Author
-
Ryotaro Yoneoka, Kenichiro Takeda, Hajime Kasai, Toshihiko Sugiura, Kohei Shikano, Mitsuhiro Abe, and Takuji Suzuki
- Subjects
BRONCHIAL arteries ,LITERATURE reviews ,PULMONARY aspergillosis ,HEMOPTYSIS ,THROMBOSIS ,ARTERIAL occlusions ,PLEURAL effusions - Abstract
Objective: Management of emergency care Background: Hemoptysis due to airway hemorrhage is treated with hemostatic agents, bronchial artery embolization (BAE), or surgical resection. We present the case of a 65-year-old man with refractory hemoptysis associated with chronic progressive pulmonary aspergillosis (CPPA) who failed to respond to combined endobronchial occlusion (EBO) with endobronchial Watanabe spigot (EWS) and BAE. Case Report: A 63-year-old man was diagnosed with CPPA in the right upper lung and presented to our hospital 2 years later for hemoptysis at age 65. He developed severe hemoptysis during an outpatient visit, and was urgently admitted, intubated, and ventilated to prevent choking on blood clots. Chest computed tomography showed a large mass in the apical portion of the right lung, constituting apical pleural thickening and an encapsulated pleural effusion, and dilatation in the bronchial artery supplying the right upper lung lobe. Bronchoscopy revealed the right upper lobe B1-B3 as the bleeding source. The patient had recurrent hemoptysis that was not controlled by BAE or 6 EBO+EWS procedures, and he ultimately died of hypoxemia. In the literature review, EBO+EWS can effectively control hemoptysis in appropriate cases, without the need for BAE or surgical lung resection. It is less invasive, is associated with fewer adverse events than BAE or surgery, and can achieve temporary hemostasis for severe hemoptysis. Conclusions: BAE and EBO+EWS were ineffective in controlling recurrent hemoptysis caused by CPPA in this case. However, a multidisciplinary approach such as attempting hemostasis with combined EBO+EWS and BAE may be a viable treatment option in severe cases of hemoptysis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Impaired Dynamic Response of Oxygen Saturation During the 6-min Walk Test Is Associated With Mortality in Chronic Fibrosing Interstitial Pneumonia
- Author
-
Soh Imamura, Takeshi Inagaki, Mitsuhiro Abe, Jiro Terada, Takeshi Kawasaki, Kengo Nagashima, Koichiro Tatsumi, and Takuji Suzuki
- Subjects
Pulmonary and Respiratory Medicine ,General Medicine ,Critical Care and Intensive Care Medicine - Published
- 2023
28. A 512Gb 3b/Cell 3D flash memory on a 96-word-line-layer technology.
- Author
-
Hiroshi Maejima, Kazushige Kanda, Susumu Fujimura, Teruo Takagiwa, Susumu Ozawa, Jumpei Sato, Yoshihiko Shindo, Manabu Sato, Naoaki Kanagawa, Junji Musha, Satoshi Inoue, Katsuaki Sakurai, Naohito Morozumi, Ryo Fukuda, Yuui Shimizu, Toshifumi Hashimoto, Xu Li, Yuki Shimizu, Kenichi Abe, Tadashi Yasufuku, Takatoshi Minamoto, Hiroshi Yoshihara, Takahiro Yamashita, Kazuhiko Satou, Takahiro Sugimoto, Fumihiro Kono, Mitsuhiro Abe, Tomoharu Hashiguchi, Masatsugu Kojima, Yasuhiro Suematsu, Takahiro Shimizu, Akihiro Imamoto, Naoki Kobayashi 0004, Makoto Miakashi, Kouichirou Yamaguchi, Sanad Bushnaq, Hicham Haibi, Masatsugu Ogawa, Yusuke Ochi, Kenro Kubota, Taichi Wakui, Dong He, Weihan Wang, Hiroe Minagawa, Tomoko Nishiuchi, Hao Nguyen, Kwang-Ho Kim, Ken Cheah, Yee Lih Koh, Feng Lu, Venky Ramachandra, Srinivas Rajendra, Steve Choi, Keyur Payak, Namas Raghunathan, Spiros Georgakis, Hiroshi Sugawara, Seungpil Lee, Takuya Futatsuyama, Koji Hosono, Noboru Shibata, Toshiki Hisada, Tetsuya Kaneko, and Hiroshi Nakamura
- Published
- 2018
- Full Text
- View/download PDF
29. Pulmonary Veno-occlusive Disease that Developed Following Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
- Author
-
Kenichiro Takeda, Akira Naito, Toshihiko Sugiura, Masaki Ishige, Kohei Shikano, Mitsuhiro Abe, Hajime Kasai, Shota Miyakuni, Shu Yamashita, Ayako Shigeta, Seiichiro Sakao, and Takuji Suzuki
- Subjects
Internal Medicine ,General Medicine - Published
- 2023
30. Quantitative Evaluation of Changes in Three-Dimensional CT Density Distributions in Pulmonary Alveolar Proteinosis after GM-CSF Inhalation
- Author
-
Miku Oda, Kentaro Yamaura, Haruyuki Ishii, Nobutaka Kitamura, Ryushi Tazawa, Mitsuhiro Abe, Koichiro Tatsumi, Ryosuke Eda, Shotaro Kondoh, Konosuke Morimoto, Takeshi Tanaka, Etsuro Yamaguchi, Ayumu Takahashi, Shinyu Izumi, Haruhito Sugiyama, Atsushi Nakagawa, Keisuke Tomii, Masaru Suzuki, Satoshi Konno, Shinya Ohkouchi, Naoki Tode, Tomohiro Handa, Toyohiro Hirai, Yoshikazu Inoue, Toru Arai, Katsuaki Asakawa, Takahiro Tanaka, Toshinori Takada, Hirofumi Nonaka, and Koh Nakata
- Subjects
Pulmonary and Respiratory Medicine - Abstract
Background: A previous clinical trial for autoimmune pulmonary alveolar proteinosis (APAP) demonstrated that granulocyte-macrophage colony-stimulating factor (GM-CSF) inhalation reduced the mean density of the lung field on computed tomography (CT) across 18 axial slice planes at a two-dimensional level. In contrast, in this study, we challenged three-dimensional analysis for changes in CT density distribution using the same datasets. Methods: As a sub-study of the trial, CT data of 31 and 27 patients who received GM-CSF and placebo, respectively, were analyzed. To overcome the difference between various shooting conditions, a newly developed automatic lung field segmentation algorithm was applied to CT data to extract the whole lung volume, and the accuracy of the segmentation was evaluated by five pulmonary physicians independently. For normalization, the percent pixel (PP) in a certain density range was calculated as a percentage of the total number of pixels from −1,000 to 0 HU. Results: The automatically segmented images revealed that the lung field was accurately extracted except for 7 patients with minor deletion or addition. Using the change in PP from baseline to week 25 (ΔPP) as the vertical axis, we created a histogram with 143 HU bins set for each patient. The most significant difference in ΔPP between GM-CSF and placebo groups was observed in two ranges: from −1,000 to −857 and −143 to 0 HU. Conclusion: Whole lung extraction followed by density histogram analysis of ΔPP may be an appropriate evaluation method for assessing CT improvement in APAP.
- Published
- 2022
31. Sequential administration of PD‑1 inhibitor and cetuximab causes pneumonia
- Author
-
Makoto Arai, Mitsuhiro Abe, Shinsuke Kitahara, Noriko Sakuma, Izumi Ohno, Koji Takahashi, Chiaki Imai, Hiromi Saeki, Takuji Suzuki, Katsuhiro Uzawa, Toyoyuki Hanazawa, and Yuichi Takiguchi
- Subjects
Cancer Research ,Oncology - Published
- 2023
32. ARDS clinical practice guideline 2021
- Author
-
Sadatomo Tasaka, Shinichiro Ohshimo, Muneyuki Takeuchi, Hideto Yasuda, Kazuya Ichikado, Kenji Tsushima, Moritoki Egi, Satoru Hashimoto, Nobuaki Shime, Osamu Saito, Shotaro Matsumoto, Eishu Nango, Yohei Okada, Kenichiro Hayashi, Masaaki Sakuraya, Mikio Nakajima, Satoshi Okamori, Shinya Miura, Tatsuma Fukuda, Tadashi Ishihara, Tetsuro Kamo, Tomoaki Yatabe, Yasuhiro Norisue, Yoshitaka Aoki, Yusuke Iizuka, Yutaka Kondo, Chihiro Narita, Daisuke Kawakami, Hiromu Okano, Jun Takeshita, Keisuke Anan, Satoru Robert Okazaki, Shunsuke Taito, Takuya Hayashi, Takuya Mayumi, Takero Terayama, Yoshifumi Kubota, Yoshinobu Abe, Yudai Iwasaki, Yuki Kishihara, Jun Kataoka, Tetsuro Nishimura, Hiroshi Yonekura, Koichi Ando, Takuo Yoshida, Tomoyuki Masuyama, Masamitsu Sanui, Takuro Nakashima, Aiko Masunaga, Aiko Tanaka, Akihiko Inoue, Akiko Higashi, Atsushi Tanikawa, Atsushi Ujiro, Chihiro Takayama, Daisuke Kasugai, Daisuke Ueno, Daizoh Satoh, Shinichi Kai, Kohei Ota, Yoshihiro Hagiwara, Jun Hamaguchi, Ryo Fujii, Takashi Hongo, Naohisa Masunaga, Ryohei Yamamoto, Ryo Uchimido, Tetsuro Terayama, Satoshi Hokari, Hitoshi Sakamoto, null Dongli, Emiko Nakataki, Erina Tabata, Seisuke Okazawa, Futoshi Kotajima, Go Ishimaru, Haruhiko Hoshino, Hideki Yoshida, Hidetaka Iwai, Hiroaki Nakagawa, Hiroko Sugimura, Hiromichi Narumiya, Hiroshi Nakamura, Hiroshi Sugimoto, Hiroyuki Hashimoto, Hiroyuki Ito, Hisashi Dote, Hisashi Imahase, Hitoshi Sato, Masahiro Katsurada, Ichiro Osawa, Jun Kamei, Jun Maki, Jun Sugihara, Junichi Fujimoto, Junichi Ishikawa, Junko Kosaka, Junpei Shibata, Katsuhiko Hashimoto, Yasushi Nakano, Kazuki Kikuyama, Kazushige Shimizu, Kazuya Okada, Keishi Kawano, Keisuke Ota, Ken-ichi Kano, Kengo Asano, Kenichi Hondo, Kenji Ishii, Kensuke Fujita, Kenta Ogawa, Kentaro Ito, Kentaro Tokunaga, Kenzo Ishii, Kohei Kusumoto, Kohei Takimoto, Kohei Yamada, Koichi Naito, Koichi Yamashita, Koichi Yoshinaga, Kota Yamauchi, Maki Murata, Makiko Konda, Manabu Hamamoto, Masaharu Aga, Masahiro Kashiura, Masami Ishikawa, Masayuki Ozaki, Michihiko Kono, Michihito Kyo, Minoru Hayashi, Mitsuhiro Abe, Mitsunori Sato, Mizu Sakai, Motoshi Kainuma, Naoki Tominaga, Naoya Iguchi, Natsuki Nakagawa, Nobumasa Aoki, Norihiro Nishioka, Norihisa Miyashita, Nozomu Seki, Ryo Ikebe, Ryosuke Imai, Ryota Tate, Ryuhei Sato, Sachiko Miyakawa, Satoshi Kazuma, Satoshi Nakano, Satoshi Tetsumoto, Satoshi Yoshimura, Shigenori Yoshitake, Shin-etsu Hoshi, Shingo Ohki, Shintaro Sato, Shodai Yoshihiro, Shoichi Ihara, Shota Yamamoto, Shunichi Koide, Shunsuke Kimata, Shunsuke Saito, Shunsuke Yasuo, Shusuke Sekine, Soichiro Mimuro, Soichiro Wada, Sosuke Sugimura, Tadashi Kaneko, Tadashi Nagato, Takaaki Maruhashi, Takahiro Tamura, Takanori Ohno, Takashi Ichiyama, Takashi Niwa, Takashi Ueji, Takayuki Ogura, Takeshi Kawasaki, Takeshi Tanaka, Takeshi Umegaki, Taku Furukawa, Taku Omura, Takumi Nagao, Takuya Taniguchi, Takuya Yoshida, Tatsutoshi Shimatani, Teppei Murata, Tetsuya Sato, Tohru Sawamoto, Yoshifumi Koukei, Tomohiro Takehara, Tomomi Ueda, Tomoya Katsuta, Tomoya Nishino, Toshiki Yokoyama, Ushio Higashijima, Wataru Iwanaga, Yasushi Inoue, Yoshiaki Iwashita, Yoshie Yamada, Yoshihiro Suido, Yoshihiro Tomioka, Yoshihisa Fujimoto, Yoshihito Fujita, Yoshikazu Yamaguchi, Yoshimi Nakamura, Yoshitomo Eguchi, Yoshiyasu Oshima, Yosuke Fukuda, Yuichi Yasufuku, Yuji Shono, Yuka Nakatani, Yuki Nakamori, Yukie Ito, Yuko Tanabe, Yusuke Nagamine, Yuta Nakamura, and Yutaro Kurihara
- Subjects
Adult ,Pulmonary and Respiratory Medicine ,Respiratory Distress Syndrome ,Extracorporeal Membrane Oxygenation ,Prone Position ,Tidal Volume ,Humans ,Child ,Critical Care and Intensive Care Medicine ,Respiration, Artificial - Abstract
Background The joint committee of the Japanese Society of Intensive Care Medicine/Japanese Respiratory Society/Japanese Society of Respiratory Care Medicine on ARDS Clinical Practice Guideline has created and released the ARDS Clinical Practice Guideline 2021. Methods The 2016 edition of the Clinical Practice Guideline covered clinical questions (CQs) that targeted only adults, but the present guideline includes 15 CQs for children in addition to 46 CQs for adults. As with the previous edition, we used a systematic review method with the Grading of Recommendations Assessment Development and Evaluation (GRADE) system as well as a degree of recommendation determination method. We also conducted systematic reviews that used meta-analyses of diagnostic accuracy and network meta-analyses as a new method. Results Recommendations for adult patients with ARDS are described: we suggest against using serum C-reactive protein and procalcitonin levels to identify bacterial pneumonia as the underlying disease (GRADE 2D); we recommend limiting tidal volume to 4–8 mL/kg for mechanical ventilation (GRADE 1D); we recommend against managements targeting an excessively low SpO2 (PaO2) (GRADE 2D); we suggest against using transpulmonary pressure as a routine basis in positive end-expiratory pressure settings (GRADE 2B); we suggest implementing extracorporeal membrane oxygenation for those with severe ARDS (GRADE 2B); we suggest against using high-dose steroids (GRADE 2C); and we recommend using low-dose steroids (GRADE 1B). The recommendations for pediatric patients with ARDS are as follows: we suggest against using non-invasive respiratory support (non-invasive positive pressure ventilation/high-flow nasal cannula oxygen therapy) (GRADE 2D), we suggest placing pediatric patients with moderate ARDS in the prone position (GRADE 2D), we suggest against routinely implementing NO inhalation therapy (GRADE 2C), and we suggest against implementing daily sedation interruption for pediatric patients with respiratory failure (GRADE 2D). Conclusions This article is a translated summary of the full version of the ARDS Clinical Practice Guideline 2021 published in Japanese (URL: https://www.jsicm.org/publication/guideline.html). The original text, which was written for Japanese healthcare professionals, may include different perspectives from healthcare professionals of other countries.
- Published
- 2022
33. Clinical Characteristics and Risk Factors of Lung Injury Induced by Nab-Paclitaxel
- Author
-
Keiichiro Yoshioka, Mitsuhiro Abe, Yuki Shiko, Ken Koshikawa, Yohei Kawasaki, Shunichiro Iwasawa, Jiro Terada, Kenji Tsushima, Koichiro Tatsumi, and Takuji Suzuki
- Subjects
Pharmacology ,Drug Design, Development and Therapy ,Paclitaxel ,Risk Factors ,Albumins ,Antineoplastic Combined Chemotherapy Protocols ,Drug Discovery ,Humans ,Pharmaceutical Science ,Lung Injury ,Middle Aged ,Retrospective Studies - Abstract
Keiichiro Yoshioka,1 Mitsuhiro Abe,1 Yuki Shiko,2 Ken Koshikawa,1 Yohei Kawasaki,2 Shunichiro Iwasawa,1 Jiro Terada,1,3 Kenji Tsushima,3 Koichiro Tatsumi,1 Takuji Suzuki1 1Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan; 2Biostatistics Section, Clinical Research Center, Chiba University Hospital, Chiba, Japan; 3Department of Pulmonary Medicine, International University of Health and Welfare, School of Medicine, Chiba, JapanCorrespondence: Mitsuhiro Abe, Department of Respirology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana Chuo-ku, Chiba, 260-8670, Japan, Tel +81 43 222 2576, Fax +81 43 226 2176, Email mthrsgnm@chiba-u.jpBackground/Aim: Nab-paclitaxel (Nab-PTX) has been widely used to treat several advanced cancers. Nab-PTX can cause drug-induced lung injury (DILI); however, its clinical and radiographic features have not been clarified. We aimed to assess the clinical characteristics of Nab-PTX-induced lung injury and identify its associated risk factors.Patients and Methods: We retrospectively investigated 304 patients who received Nab-PTX at Chiba University Hospital between November 2010 and November 2017. We obtained information regarding the clinical course, laboratory findings, and chest computed tomography findings from their medical records.Results: Forty-one patients (13%) developed DILI. Grade 1 lung injury occurred in 27 patients (8.8%), grade 2, 8 patients (2.6%); grade 3, 3 patients (0.9%); grade 4, 1 (0.3%); and grade 5, 2 (0.6%). Multivariate analysis revealed that age > 56 years (odds ratio [OR]: 3.0), pre-existing interstitial lung changes (OR: 3.2), and combined drugs with gemcitabine (OR: 2.7) were independent risk factors for DILI owing to Nab-PTX administration.Conclusion: Nab-PTX-induced lung injury is not rare; however, most cases are asymptomatic (grade 1). Older age, pre-existing interstitial lung changes, and combined drugs with gemcitabine could increase the incidence of Nab-PTX-induced lung injury; such patients should be treated with greater care.Keywords: drug-induced lung injury, gemcitabine, multivariate analysis, nab-paclitaxel, risk factor
- Published
- 2022
34. A Comparison of Clinical Presentations in Coronavirus Disease 2019 Caused by Different Omicron Variants in Japan: A Retrospective Study.
- Author
-
Ryutaro Hirama, Kenichiro Takeda, Seiichiro Sakao, Hajime Kasai, Shizu Miyata, Kohei Shikano, Akira Naito, Mitsuhiro Abe, Takeshi Kawasaki, Ayako Shigeta, Taka-aki Nakada, Hidetoshi Igari, and Takuji Suzuki
- Published
- 2023
- Full Text
- View/download PDF
35. Membrane–protein Interactions Under Closed and Open Systems
- Author
-
Akane Iida, Mitsuhiro Abe, and Hideki Nabika
- Subjects
Pharmacology (medical) - Published
- 2022
36. A case of sarcoidosis with multiple axial skeleton lesion detected by FDG-PET
- Author
-
Yuri Isaka, Jiro Terada, Masayuki Ota, Keiichiro Yoshioka, Mitsuhiro Abe, Takeshi Kawasaki, Junichiro Ikeda, and Koichiro Tatsumi
- Published
- 2021
37. DNA‐Based Synthetic Growth Factor Surrogates with Fine‐Tuned Agonism**
- Author
-
Masataka Yanagawa, Momoko Akiyama, Mitsuhiro Abe, Yasushi Sako, Michio Hiroshima, Shinsuke Sando, and Ryosuke Ueki
- Subjects
Agonist ,medicine.drug_class ,Aptamer ,medicine.medical_treatment ,Computational biology ,Ligands ,Partial agonist ,Catalysis ,chemistry.chemical_compound ,Cell Movement ,Human Umbilical Vein Endothelial Cells ,medicine ,Humans ,Agonism ,Receptors, Cytokine ,Receptor ,Hepatocyte Growth Factor ,Chemistry ,Growth factor ,General Medicine ,General Chemistry ,Aptamers, Nucleotide ,Proto-Oncogene Proteins c-met ,Microscopy, Fluorescence ,A549 Cells ,Intercellular Signaling Peptides and Proteins ,Signal transduction ,Dimerization ,DNA ,Protein Binding ,Signal Transduction - Abstract
Designing synthetic surrogates of functional proteins is an important, albeit challenging, task in the field of chemistry. A strategy toward the design of synthetic agonists for growth factor or cytokine receptors that elicit a desired signal activity has been in high demand, as such ligands hold great promise as safer and more effective therapeutics. In the present study, we used a DNA aptamer as a building block and described the strategy-guided design of a synthetic receptor agonist with fine-tuned agonism. The developed synthetic partial agonist can regulate therapeutically relevant cellular activities by eliciting fine-tuned receptor signaling.
- Published
- 2021
38. Promoted Aggregation of Aβ on Lipid Bilayers in an Open Flowing System
- Author
-
Akane Iida, Mitsuhiro Abe, Kei Unoura, Chiaki Soga, Miona Nochi, and Hideki Nabika
- Subjects
Amyloid ,Surface Properties ,Diffusion ,Lipid Bilayers ,02 engineering and technology ,010402 general chemistry ,Fibril ,01 natural sciences ,Protein Aggregates ,Adsorption ,Desorption ,General Materials Science ,Benzothiazoles ,Physical and Theoretical Chemistry ,Lipid bilayer ,Amyloid beta-Peptides ,Chemistry ,Bilayer ,Optical Imaging ,Substrate (chemistry) ,021001 nanoscience & nanotechnology ,0104 chemical sciences ,Membrane ,Biophysics ,Thermodynamics ,Dimyristoylphosphatidylcholine ,0210 nano-technology - Abstract
Self-assembly of amyloid-β (Aβ) peptides in nonequilibrium, flowing conditions is associated with pathogenesis of Alzheimer's disease. We examined the role of biologically relevant, nonequilibrium, flowing conditions in the desorption, diffusion, and integration of Aβ-lipid assemblies at the membrane surface using a microchannel connected with microsyringes. A 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) bilayer was formed on a glass substrate and incubated in Aβ solution under either a quiescent condition (no flow) or flowing condition for 24 h. Although dot-like aggregates (
- Published
- 2021
39. Pulmonary Veno-occlusive Disease that Developed Following Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia: A Case Report
- Author
-
Kenichiro, Takeda, Akira, Naito, Toshihiko, Sugiura, Masaki, Ishige, Kohei, Shikano, Mitsuhiro, Abe, Hajime, Kasai, Shota, Miyakuni, Shu, Yamashita, Ayako, Shigeta, Seiichiro, Sakao, and Takuji, Suzuki
- Abstract
We herein report a case of pulmonary veno-occlusive disease (PVOD) induced by allo-hematopoietic stem cell transplantation (HSCT) in a 48-year-old man who was diagnosed with acute myeloid leukemia. Five months after transplantation, he developed dyspnea and was diagnosed with pulmonary hypertension based on right heart catheterization. Although he received treatment with pulmonary vasodilators, diuretics, and corticosteroids, his pulmonary artery pressure did not decrease, and his pulmonary edema worsened. Based on the clinical course, hypoxemia, diffusion impairment, and computed tomography findings, the patient was diagnosed with HSCT-related PVOD. Critical attention should be paid to dyspnea after HSCT for the early diagnosis of PVOD.
- Published
- 2022
40. Clinical Outcomes of Sotrovimab Treatment in 10 High-Risk Patients with Mild COVID-19: A Case Series
- Author
-
Kenichiro, Takeda, Hajime, Kasai, Seiichiro, Sakao, Mikihito, Saito, Kohei, Shikano, Akira, Naito, Mitsuhiro, Abe, Takeshi, Kawasaki, Misuzu, Yahaba, Toshibumi, Taniguchi, Hidetoshi, Igari, and Takuji, Suzuki
- Subjects
Adult ,Aged, 80 and over ,SARS-CoV-2 ,COVID-19 ,Humans ,General Medicine ,Middle Aged ,Antibodies, Monoclonal, Humanized ,Antibodies, Neutralizing ,Aged - Abstract
BACKGROUND Although sotrovimab reduces the risk of hospitalization or death due to COVID-19, there have been few reports of its use in clinical practice. Particularly, information on the effectiveness of sotrovimab against the omicron variant of the virus is limited. We present 10 cases of COVID-19 treated with sotrovimab at our unit between December 2021 and February 2022. CASE REPORT The age of the patients ranged from 32 to 81 years (median: 40 years). The comorbidities included lung cancer, cardiovascular disease, chronic kidney disease requiring hemodialysis, and AIDS. Two of the patients were also organ recipients. Oxygen saturation (SpO2) was above 97% in all patients. None of the patients presented with pneumonia on admission. However, blood test results showed that all patients had risk factors for severe COVID-19 outcomes. The interval from symptom onset to sotrovimab administration and resolution ranged from 2 to 5 days (median: 2 days) and 2 to 15 days (median: 5 days), respectively. Only 1 patient developed pneumonia and was treated with remdesivir after sotrovimab administration. However, this patient did not require oxygen therapy. Although no moderate to severe adverse events were observed, a mild adverse event was observed in 1 patient. CONCLUSIONS Sotrovimab could be safe and effective in preventing progression of COVID-19 in patients with a variety of underlying diseases and who are at high risk of severe disease outcomes.
- Published
- 2022
41. Prognostic value of lymphocyte counts in bronchoalveolar lavage fluid in patients with acute respiratory failure: a retrospective cohort study
- Author
-
Koichiro Tatsumi, Yuri Isaka, Takashi Shimazui, Taka-aki Nakada, Jiro Terada, Yasutaka Hirasawa, Masashi Sakayori, Kenji Tsushima, Kenichi Suzuki, Mitsuhiro Abe, Takeshi Kawasaki, and Keiichiro Yoshioka
- Subjects
medicine.medical_specialty ,Lymphocyte ,Critical Care and Intensive Care Medicine ,Acute respiratory failure ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Medicine ,030212 general & internal medicine ,Lymphocytes ,Mortality ,medicine.diagnostic_test ,Receiver operating characteristic ,business.industry ,Research ,Bronchoalveolar lavage fluid ,Hazard ratio ,Interstitial lung disease ,lcsh:Medical emergencies. Critical care. Intensive care. First aid ,Retrospective cohort study ,lcsh:RC86-88.9 ,Eosinophil ,respiratory system ,medicine.disease ,Confidence interval ,respiratory tract diseases ,Bronchoalveolar lavage ,medicine.anatomical_structure ,030228 respiratory system ,business - Abstract
BackgroundCellular patterns in bronchoalveolar lavage fluid (BALF) are used to distinguish or rule out particular diseases in patients with acute respiratory failure (ARF). However, whether BALF cellular patterns can predict mortality or not is unknown. We test the hypothesis that BALF cellular patterns have predictive value for mortality in patients with ARF.MethodsThis was a retrospective single-center observational study conducted in a Japanese University Hospital. Consecutive patients (n= 78) with both pulmonary infiltrates and ARF who were examined by bronchoalveolar lavage (BAL) between April 2015 and May 2018 with at least 1 year of follow-up were analyzed. Primary analysis was receiver operating characteristic curve—area under the curve (ROC-AUC) analysis for 1-year mortality.ResultsAmong the final sample size of 78 patients, survivors (n= 56) had significantly increased lymphocyte and eosinophil counts and decreased neutrophil counts in BALF compared with non-survivors (n= 22). Among the fractions, lymphocyte count was the most significantly different (30 [12-50] vs. 7.0 [2.9-13]%,PPPP=0.0012). Increased survival was significantly associated with ≥20% BALF lymphocytes in both interstitial lung disease (ILD) and non-ILD subgroups (P=0.0052 andP=0.0033, respectively). In secondary outcome analysis, patients with ≥20% BALF lymphocytes had significantly increased ventilator-free days, which represents less respiratory dysfunction than those with ConclusionsIn the patients with ARF, ≥20% lymphocytes in BALF was associated with significantly less ventilatory support, lower mortality at both 90-day and 1-year follow-ups.
- Published
- 2021
42. Sphingomyelin localization in the intestinal crypt surface
- Author
-
Yoshibumi Ueda, Mitsuhiro Abe, Toshiyuki Ishiwata, and Takeaki Ozawa
- Subjects
Mice ,Microscopy ,Intestine, Small ,Biophysics ,Animals ,Cell Biology ,Intestinal Mucosa ,Molecular Biology ,Biochemistry ,Sphingomyelins - Abstract
Macroscopic lipid observation in the organs of living small animals has not been realized. Here, we visualized sphingomyelin (SM) in the intestines of living mice using an SM-binding protein (EqtII-EGFP-His) under two-photon microscopy. The SM was identified as 10 μm spots in glands of the lamina propria of the mucosa in the large and small intestines. The spots vertically penetrated from the serosa toward the mucosal side. At the edge of the mucosal side in the small intestine, these spots connected with each other and formed horizontal lines. For the large intestine, the horizontal lines became a surface, indicating that SM covered the whole crypt membrane. Detailed observation revealed thin SM-positive lines that connected the spots and the blood vessels in the small intestine. Thus, SM exists at crypt surfaces and inside crypts of the intestines and can regulate the functions of the digestion system.
- Published
- 2022
43. Feasibility and accuracy of rapid on-site evaluation of touch imprint cytology during transbronchial biopsy
- Author
-
Fumie Saegusa, Yuji Tada, Tsukasa Ishiwata, Takeshi Kawasaki, Jiro Terada, Jun Ikari, Koichiro Tatsumi, Kohei Shikano, Mitsuhiro Abe, Masashi Sakayori, and Naoko Kawata
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Retrospective cohort study ,Touch imprint cytology ,Site evaluation ,Malignancy ,medicine.disease ,body regions ,03 medical and health sciences ,0302 clinical medicine ,030228 respiratory system ,Bronchoscopy ,030220 oncology & carcinogenesis ,Cytology ,mental disorders ,Biopsy ,medicine ,Original Article ,Radiology ,Transbronchial biopsy ,business ,human activities - Abstract
Background Rapid on-site evaluation (ROSE) of cytologic material is widely performed because it provides clinicians with instant diagnostic information. However, the utility of ROSE of touch imprint cytology (ROSE-TIC) during transbronchial biopsy (TBB) remains unclear. The aim of this study was to evaluate the feasibility and accuracy of ROSE-TIC for TBB. Methods A retrospective study was performed on patients who underwent diagnostic bronchoscopy combined with ROSE-TIC. The results of ROSE-TIC, diagnosed as either positive or negative for malignancy, were compared with the histological findings and final diagnosis. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy were calculated. The success rate of molecular testing on TBB specimens was also assessed. Results Overall, 460 patients underwent bronchoscopy with ROSE-TIC. Of these, 377 cases (82.0%) were malignant and 83 cases (18.0%) were non-malignant in the final diagnosis. Compared with the histological findings, ROSE-TIC showed sensitivity, specificity, PPV, NPV, and diagnostic accuracy values of 91.1%, 90.4%, 94.8%, 84.0%, and 90.9%, respectively. Compared with the final diagnosis, ROSE-TIC showed sensitivity, specificity, PPV, NPV, and diagnostic accuracy values of 75.3%, 91.6%, 97.6%, 45.0%, and 78.3%, respectively. Seven discordant cases (1.5%) were positive on ROSE-TIC and negative on final diagnosis. The success rates for molecular analysis from TBB samples were 96.6% for EGFR mutation, 87.3% for ALK rearrangement, 93.1% for ROS1 rearrangement, and 96.2% for PD-L1 expression. Conclusions The accuracy of ROSE-TIC is high. It can be useful for obtaining instant diagnosis, contributing to a high success rate of molecular analysis for targeted therapy.
- Published
- 2020
44. Thrombomodulin Alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Randomized, Double-Blind Placebo-controlled Trial
- Author
-
Tetsuji Kawamura, Sakae Homma, Hiroyuki Taniguchi, Arata Azuma, Yoshikazu Inoue, Noriho Sakamoto, Kiminori Fujimoto, Masaki Okamoto, Natsuki Yamamori, Masahito Ebina, Jun Araya, Yoshio Taguchi, Shinji Abe, Yoshihito Yamada, Mitsuhiro Abe, Yasuhiro Kondoh, Kenji Tsushima, Machiko Arita, Hiroyoshi Yamauchi, Joe Shindoh, Susumu Sakamoto, Shinyu Izumi, Jun Tagawa, Yasuo Matsuzawa, Hiroshi Ishii, Masahiro Aoshima, Takafumi Suda, Naozumi Hashimoto, Takeshi Johkoh, Yuji Tohda, Kazuma Kishi, Koji Bessho, Takashi Ogura, Keisuke Tomii, Takefumi Saito, and Kazuya Ichikado
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Exacerbation ,business.industry ,Placebo-controlled study ,Critical Care and Intensive Care Medicine ,medicine.disease ,Thrombomodulin ,Gastroenterology ,Pathogenesis ,Clinical trial ,03 medical and health sciences ,Idiopathic pulmonary fibrosis ,0302 clinical medicine ,030228 respiratory system ,Thrombomodulin Alfa ,Coagulation ,Internal medicine ,Medicine ,030212 general & internal medicine ,business - Abstract
Rationale: Acute exacerbation during the course of idiopathic pulmonary fibrosis causes a poor prognosis. Coagulation abnormalities and endothelial damage are involved in its pathogenesis. Thrombom...
- Published
- 2020
45. Clinical characteristics and risk factors of drug‐induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis
- Author
-
Koichiro Tatsumi, Shunichiro Iwasawa, Jiro Terada, Yohei Kawasaki, Yasutaka Hirasawa, Keiichiro Yoshioka, Hajime Kasai, Mitsuhiro Abe, Masashi Sakayori, Kenji Tsushima, and Ken Koshikawa
- Subjects
0301 basic medicine ,Alectinib ,Male ,Lung Neoplasms ,Single Center ,0302 clinical medicine ,Piperidines ,Risk Factors ,hemic and lymphatic diseases ,Antineoplastic Combined Chemotherapy Protocols ,Anaplastic lymphoma kinase ,Anaplastic Lymphoma Kinase ,Sulfones ,General Medicine ,Lung Injury ,Middle Aged ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Prognosis ,Survival Rate ,Oncology ,030220 oncology & carcinogenesis ,Carcinoma, Squamous Cell ,Original Article ,Female ,medicine.drug ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Drug-Related Side Effects and Adverse Reactions ,Carbazoles ,Adenocarcinoma of Lung ,Lung injury ,lcsh:RC254-282 ,03 medical and health sciences ,Crizotinib ,Internal medicine ,medicine ,ceritinib ,Humans ,Lung cancer ,Protein Kinase Inhibitors ,Aged ,Retrospective Studies ,Ceritinib ,business.industry ,Gene rearrangement ,Original Articles ,medicine.disease ,respiratory tract diseases ,030104 developmental biology ,Pyrimidines ,drug‐related side effects and adverse reactions ,business ,Follow-Up Studies - Abstract
Background If anaplastic lymphoma kinase (ALK) gene rearrangement in lung cancer is identified, ALK‐tyrosine kinase inhibitors (ALK‐TKIs) can be an effective treatment. However, the details of drug‐induced lung injury (DILI) caused by ALK‐TKI, which can be a serious side effect of ALK‐TKIs, remains unclear. This study aimed to investigate the clinical features and the onset risk factors of DILI by ALK‐TKIs in clinical practice. Methods The clinical features of 56 consecutive patients who received crizotinib, alectinib, and/or ceritinib at our hospital from 2012 to 2018 were retrospectively examined. Among these, patients diagnosed with DILI due to ALK‐TKIs were evaluated in terms of clinical features and parameters. Each clinical parameter before the administration of ALK‐TKIs was compared between the DILI onset group and the non‐onset group. Results A total of seven cases were diagnosed with DILI due to ALK‐TKIs; no DILI‐related deaths were observed. Chest computed tomography (CT) scan findings identified six patients with the organizing pneumonia (OP) pattern and one with the hypersensitivity pneumonia pattern. The onset of DILI was significantly different in patients age ≥ 64 years and with a creatinine clearance
- Published
- 2020
46. Pneumocystis Pneumonia in an Immunocompetent Patient Developing a Subacute Course with Central Consolidation
- Author
-
Chiaki Kawame, Hidehiro Yokota, Kohei Shikano, Hajime Kasai, Masaki Suzuki, Mitsuhiro Abe, Takashi Kishimoto, Jun-ichiro Ikeda, Seiichiro Sakao, and Takuji Suzuki
- Published
- 2022
47. What are the factors affecting the recovery rate of bronchoalveolar lavage fluid?
- Author
-
Yuki Shiko, Mitsuhiro Abe, Yohei Kawasaki, Koichiro Tatsumi, Takeshi Kawasaki, Jiro Terada, Kohei Shikano, Keiichiro Yoshioka, Jun Ikari, Kenji Tsushima, and Tsukasa Ishiwata
- Subjects
Pulmonary and Respiratory Medicine ,Spirometry ,Male ,medicine.medical_specialty ,Vital capacity ,Gastroenterology ,Bronchoalveolar Lavage ,Pulmonary function testing ,Internal medicine ,medicine ,Immunology and Allergy ,Humans ,Genetics (clinical) ,Aged ,Retrospective Studies ,Bronchus ,medicine.diagnostic_test ,business.industry ,Interstitial lung disease ,Odds ratio ,respiratory system ,medicine.disease ,Confidence interval ,respiratory tract diseases ,Respiratory Function Tests ,medicine.anatomical_structure ,Bronchoalveolar lavage ,business ,Lung Diseases, Interstitial ,Bronchoalveolar Lavage Fluid - Abstract
• • BACKGROUND: Bronchoalveolar lavage (BAL) is a useful examination for the evaluation of interstitial lung disease. A high BAL fluid (BALF) recovery rate is desirable because low recovery rates lead to inaccurate diagnoses and increased adverse events. Few studies have explored whether BALF recovery rates are influenced by clinical factors. OBJECTIVES This study aimed to identify the clinical parameters affecting the recovery rates of BALF and the extent of their effects. METHOD Data from patients who underwent BAL at the Chiba University Hospital between 2013 and 2019 were retrospectively reviewed. BAL was performed with three aliquots of 50 mL physiological saline. The potential association of the BALF recovery rate with clinical parameters; age, sex, smoking status, underlying disease, bronchus used for the procedure, and pulmonary function, was analyzed. RESULTS 826 patients had undergone BAL. The average recovery rate was 52.4%. Factors affecting BALF recovery rates included male sex (odds ratio [OR]: 0.32, 95% confidence interval [CI]: 0.20-0.53, p < 0.001); age ≥ 65 years (OR: 0.50, 95% CI: 0.33-0.76, p < 0.001); use of the left bronchus (OR: 0.46, 95% CI: 0.30-0.71, p = 0.001) and bronchi other than the middle lobe bronchus or lingula (OR: 0.41, 95% CI: 0.25-0.65, p < 0.001); and forced expiratory volume in 1 second divided by forced vital capacity < 80% (OR: 0.42, 95% CI: 0.40-1.00, p < 0.001). CONCLUSION Sex, age, bronchus used for the procedure, and pulmonary function may be useful as pre-procedural predictors of BALF recovery rates.
- Published
- 2021
48. Frontispiece: DNA‐Based Synthetic Growth Factor Surrogates with Fine‐Tuned Agonism
- Author
-
Masataka Yanagawa, Mitsuhiro Abe, Michio Hiroshima, Shinsuke Sando, Ryosuke Ueki, Momoko Akiyama, and Yasushi Sako
- Subjects
chemistry.chemical_compound ,Chemistry ,Aptamer ,Growth factor ,medicine.medical_treatment ,medicine ,Biophysics ,Agonism ,General Chemistry ,Signal transduction ,Receptor ,Catalysis ,DNA - Published
- 2021
49. Frontispiz: DNA‐Based Synthetic Growth Factor Surrogates with Fine‐Tuned Agonism
- Author
-
Momoko Akiyama, Ryosuke Ueki, Masataka Yanagawa, Mitsuhiro Abe, Michio Hiroshima, Yasushi Sako, and Shinsuke Sando
- Subjects
General Medicine - Published
- 2021
50. Longitudinal structural changes using MDCT in patients with combined pulmonary fibrosis with emphysema
- Author
-
Hirotaka Sato, Koichiro Tatsumi, Takuji Suzuki, Ayako Shimada, Hideaki Haneishi, Hajime Yokota, Naoko Kawata, Masaki Suzuki, Mitsuhiro Abe, and Shin Matsuoka
- Subjects
medicine.medical_specialty ,business.industry ,Pulmonary fibrosis ,Medicine ,In patient ,Radiology ,business ,medicine.disease - Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.